Rebeca Nieto-Nieto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Rebeca Nieto-Nieto has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Ana Serrano-Combarro
Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Inmunopathology group, IDIVAL, Santander, Spain
1 shared publication - Belén Atienza-Mateo
Rheumatology Service, Immunopathology Group, Department of Medicine and Psychiatry, Hospital Universitario Marqués de Valdecilla, IDIVAL, University of Cantabria, Santander, Spain
1 shared publication - Carolina Aguirre Portilla
Immunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL, 39011 Santander, Spain
1 shared publication - Clara Vaquera-Illescas
Immunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL, 39011 Santander, Spain
1 shared publication - David Iturbe-Fernández
Respiratory Department Marqués de Valdecilla University Hospital Santander Spain
1 shared publication - Joao Carlos Batista-Liz
Immunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL, 39011 Santander, Spain
1 shared publication
Latest Publications
- Open Access
- 4 November 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (21) , 10722
A New Approach for Achieving Earlier and More Accurate Diagnosis of Connective Tissue Disease-Related Interstitial Lung Disease: TGFB and PDGFA as Novel Promising Biomarkers
An early and accurate diagnosis of connective tissue diseases-related interstitial lung disease (CTD-ILD) is crucial for delaying lung fibrosis, but its unknown etiology and the limitations of clinical tools make it challenging for clinicians. PDGF and TGFB are the main profibrotic genes. We evaluated PDGFA, TGFB1, TGFB2, and TGFB3 role in the diagnosis of ILD associated with rheumatoid arthritis (RA), systemic sclerosis (SSc), and inflammatory myopathies (IM). Blood was collected from 289 patients:33 RA-ILD, 31 SSc-ILD, 29 IM-ILD; and 22 RA-nonILD, 18 SSc-nonILD, 8 IM-nonILD; and 148 idiopathic pulmonary fibrosis (IPF). The relative expression was quantified by qPCR. Lower PDGFA, TGFB1, and TGFB2 expression differentiated RA-ILD from RA-nonILD patients, acting as ILD early diagnostic biomarkers in RA with cut-offs of TGFB2 expression compared to SSc-nonILD patients, with a cut-off of 0.0166 and >0.001547, respectively. PDGFA and TGFB2, as well as TGFB2 and TGFB3 expression were associated with RA-ILD and SSc-ILD prognosis, respectively. PDGFA and TGFB are promising blood biomarkers with clinical value for the early and accurate CTD-ILD diagnosis.
- 4 November 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (21) , 10722
Open AccessA New Approach for Achieving Earlier and More Accurate Diagnosis of Connective Tissue Disease-Related Interstitial Lung Disease: TGFB and PDGFA as Novel Promising Biomarkers
An early and accurate diagnosis of connective tissue diseases-related interstitial lung disease (CTD-ILD) is crucial for delaying lung fibrosis, but its unknown etiology and the limitations of clinical tools make it challenging for clinicians. PDGF and TGFB are the main profibrotic genes. We evaluated PDGFA, TGFB1, TGFB2, and TGFB3 role in the diagnosis of ILD associated with rheumatoid arthritis (RA), systemic sclerosis (SSc), and inflammatory myopathies (IM). Blood was collected from 289 patients:33 RA-ILD, 31 SSc-ILD, 29 IM-ILD; and 22 RA-nonILD, 18 SSc-nonILD, 8 IM-nonILD; and 148 idiopathic pulmonary fibrosis (IPF). The relative expression was quantified by qPCR. Lower PDGFA, TGFB1, and TGFB2 expression differentiated RA-ILD from RA-nonILD patients, acting as ILD early diagnostic biomarkers in RA with cut-offs of TGFB2 expression compared to SSc-nonILD patients, with a cut-off of 0.0166 and >0.001547, respectively. PDGFA and TGFB2, as well as TGFB2 and TGFB3 expression were associated with RA-ILD and SSc-ILD prognosis, respectively. PDGFA and TGFB are promising blood biomarkers with clinical value for the early and accurate CTD-ILD diagnosis.